CancerDrs Find care

Sarcoma clinical trials

289 actively recruiting sarcoma trials in the United States. Rare cancers of bone and soft tissue. Many subtypes with distinct biology. Specialized sarcoma centers often run trials unavailable elsewhere.

Data from ClinicalTrials.gov · last refreshed · Sarcoma stats on SEER

77
Phase 1
103
Phase 2
12
Phase 3
97
Other

Sarcoma by the numbers (U.S.)

13,520
Estimated new cases (2025)
5,410
Estimated deaths (2025)
66%
5-year relative survival
62
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse sarcoma trials by state

California 94 Texas 94 New York 81 Florida 62 Ohio 59 Pennsylvania 50 Maryland 48 Tennessee 47 Massachusetts 46 Missouri 41 Minnesota 39 Illinois 37 North Carolina 36 Michigan 34 New Jersey 33 Arizona 32 Colorado 31 Georgia 31 Washington 28 District of Columbia 24 Virginia 24 Utah 23 Wisconsin 22 Oregon 17 Alabama 16 Connecticut 16 Louisiana 15 Indiana 14 Oklahoma 14 Iowa 13 South Carolina 13 Kentucky 11 Nebraska 11 Arkansas 10 North Dakota 10 South Dakota 10 Kansas 9 Nevada 9 Rhode Island 9 Hawaii 8 New Hampshire 7 Maine 6 New Mexico 6 Delaware 5 Idaho 5 Montana 5 Mississippi 4 Vermont 4 West Virginia 4 Alaska 3 Wyoming 2

Top trials by phase + site coverage

Phase 3 Recruiting NIH

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Locations:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona

+ 235 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Providence Alaska Medical Center — Anchorage, Alaska
  • Kingman Regional Medical Center — Kingman, Arizona

+ 216 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 167 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…

Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 161 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • City of Hope Comprehensive Cancer Center — Duarte, California

+ 103 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…

Sponsor: NRG Oncology
NCT ID: NCT05646316
Locations:
  • George Washington University Medical Center — Washington D.C., District of Columbia
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida

+ 52 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Sponsor: Polaris Group
NCT ID: NCT05712694
Locations:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • USC Norris comprehensive cancer center — Los Angeles, California
  • Stanford University Medical Centre — Palo Alto, California

+ 23 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…

Sponsor: PharmaMar
NCT ID: NCT06088290
Locations:
  • Mayo Clinic Hospital - Phoenix — Phoenix, Arizona
  • Precision NextGen Oncology & Research Center — Beverly Hills, California
  • Cedars-Sinai Medical Center — Los Angeles, California

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…

Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Locations:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • University of California Los Angeles — Los Angeles, California
  • Sarcoma Oncology Center — Santa Monica, California

+ 14 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Locations:
  • CBCC Global Research, Inc. ( Site 0123) — Bakersfield, California
  • Beverly Hills Cancer Center ( Site 0116) — Beverly Hills, California
  • Stamford Hospital ( Site 0136) — Stamford, Connecticut

+ 12 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).

Sponsor: Rezolute
NCT ID: NCT06881992
Locations:
  • Investigative Site — Chicago, Illinois
  • Investigative Site — Bethesda, Maryland
  • Investigative Site — Boston, Massachusetts

+ 5 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course va…

Sponsor: University of Utah
NCT ID: NCT03422198
Locations:
  • Stanford Cancer Center — Palo Alto, California
  • Loyola University Medical Center — Maywood, Illinois
  • MD Anderson — Houston, Texas

+ 2 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 289 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20